NASDAQ:AZRXAzurRx BioPharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AzurRx BioPharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.83 0.00 (0.00 %) (As of 07/10/2020 11:10 AM ET) Add Compare Share Today's Range$0.83Now: $0.83▼$0.8750-Day Range$0.80MA: $0.90▼$1.0252-Week Range$0.37Now: $0.83▼$1.94Volume29,367 shsAverage Volume139,875 shsMarket Capitalization$23.47 millionP/E RatioN/ADividend YieldN/ABeta2.03 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAzurRx BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, AzurRx BioPharma has a potential upside of 200.4% from its current price of $0.83.Amount of Analyst CoverageAzurRx BioPharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesAzurRx BioPharma has received 214 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAzurRx BioPharma has received 142 “underperform” votes. (Add your “underperform” vote.)Community SentimentAzurRx BioPharma has received 60.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote “Outperform” if you believe AZRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAzurRx BioPharma does not currently pay a dividend.Dividend GrowthAzurRx BioPharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AzurRx BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of AzurRx BioPharma is held by insiders.Percentage Held by InstitutionsOnly 5.16% of the stock of AzurRx BioPharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AzurRx BioPharma are expected to grow in the coming year, from ($0.50) to ($0.41) per share.Price to Book Value per Share RatioAzurRx BioPharma has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AZRX Previous Symbol CUSIPN/A CIK1604191 Webwww.azurrx.com Phone646-699-7855Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book4.89Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-15,180,000.00 Net MarginsN/A Return on Equity-457.07% Return on Assets-174.66%Miscellaneous Employees12 Outstanding Shares28,200,000Market Cap$23.47 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:AZRX Rates by TradingView Receive AZRX News and Ratings via Email Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions How has AzurRx BioPharma's stock been impacted by COVID-19 (Coronavirus)? AzurRx BioPharma's stock was trading at $0.6150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AZRX shares have increased by 35.3% and is now trading at $0.8321. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of AzurRx BioPharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AzurRx BioPharma. When is AzurRx BioPharma's next earnings date? AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for AzurRx BioPharma. How were AzurRx BioPharma's earnings last quarter? AzurRx BioPharma Inc (NASDAQ:AZRX) released its earnings results on Friday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.09. View AzurRx BioPharma's earnings history. What price target have analysts set for AZRX? 3 equities research analysts have issued 1-year price objectives for AzurRx BioPharma's stock. Their forecasts range from $2.00 to $3.00. On average, they expect AzurRx BioPharma's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 200.4% from the stock's current price. View analysts' price targets for AzurRx BioPharma. Has AzurRx BioPharma been receiving favorable news coverage? Media coverage about AZRX stock has trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AzurRx BioPharma earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about AzurRx BioPharma. Are investors shorting AzurRx BioPharma? AzurRx BioPharma saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 145,500 shares, an increase of 95.6% from the May 31st total of 74,400 shares. Based on an average daily volume of 305,500 shares, the short-interest ratio is currently 0.5 days. Currently, 0.6% of the company's stock are short sold. View AzurRx BioPharma's Current Options Chain. Who are some of AzurRx BioPharma's key competitors? Some companies that are related to AzurRx BioPharma include Onconova Therapeutics (ONTX), Milestone Pharmaceuticals (MIST), Unum Therapeutics (UMRX), DiaMedica Therapeutics (DMAC), Endonovo Therapeutics (ENDV), TapImmune (MRKR), Antibe Therapeutics (ATBPF), Evoke Pharma (EVOK), Chembio Diagnostics (CEMI), Zynerba Pharmaceuticals (ZYNE), Monopar Therapeutics (MNPR), AcelRx Pharmaceuticals (ACRX), resTORbio (TORC), Legend Biotech (LTRN) and Clearside Biomedical (CLSD). View all competitors. What other stocks do shareholders of AzurRx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include Outlook Therapeutics (OTLK), Amplify Energy (AMPY), Amplify Energy (AMPY), Unum Therapeutics (UMRX), Chesapeake Energy (CHK), Trevena (TRVN), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB) and Titan Pharmaceuticals (TTNP). Who are AzurRx BioPharma's key executives? AzurRx BioPharma's management team includes the following people: Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)Mr. Daniel Dupret, Chief Scientific Officer (Age 63)Dr. Mathieu Schué Ph.D., Head of LaboratoryDr. James E. Pennington, Chief Medical Officer (Age 76) When did AzurRx BioPharma IPO? (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO. What is AzurRx BioPharma's stock symbol? AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX." How do I buy shares of AzurRx BioPharma? Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AzurRx BioPharma's stock price today? One share of AZRX stock can currently be purchased for approximately $0.83. How big of a company is AzurRx BioPharma? AzurRx BioPharma has a market capitalization of $23.47 million. AzurRx BioPharma employs 12 workers across the globe. What is AzurRx BioPharma's official website? The official website for AzurRx BioPharma is www.azurrx.com. How can I contact AzurRx BioPharma? AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
